Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 16Thoracic 1Sarcoma 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 110Pheochromocytoma 33Carcinoma, Neuroendocrine 32Pituitary Neoplasms 28Thyroid Cancer, Papillary 26Paraganglioma 26Adrenocortical Carcinoma 21Neoplasms 19Gastro-enteropancreatic neuroendocrine tumor 19Thyroid Neoplasms 17Adrenal Gland Neoplasms 16Multiple Endocrine Neoplasia Type 1 14Stomach Neoplasms 13Pancreatic Neoplasms 13Carcinoid Tumor 13Prostatic Neoplasms 12Lung Neoplasms 12Thyroid Carcinoma, Anaplastic 11Sarcoma 11Breast Neoplasms 11Adenoma, Islet Cell 11Small Cell Lung Carcinoma 10Neuroblastoma 10Neoplasm Metastasis 10Colorectal Neoplasms 10Carcinoma, Hepatocellular 10Brain Neoplasms 10Ovarian Neoplasms 9Meningioma 9Esophageal Neoplasms 9

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Clear-cell metastatic renal cell carcinoma × Endocrine × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡